Loading news...
Rhythm Pharma shares rise after Phase 3 data show strong BMI drop. FDA decision on obesity drug due by March 20.
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.72 per share a year ago.
-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) -- -- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA -- -- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2025.
Hillsdale Investment Management Inc. purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,600 shares of the company's stock, valued at approximately $4,302,000. Hillsdale Investment Management Inc. owned
RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), citing it as a commercial-stage biotech pioneering the rare genetic obesity market.
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pre-Market Stock Futures: Futures are trading lower on Thursday, as Walmart's forward outlook was disappointing. Risk-on was back on Wednesday, as the stock market, which is off to its worst start of the year versus global markets since 1995, rebounded. A combination of positive economic data, strong earnings, and relief from AI financing jitters helped... Here Are Thursday's Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More.
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.
Alphabet is poised to convert much of its record Google Cloud backlog into recognized revenue this year. BeOne Medicines could soon win approval for a powerhouse blood cancer therapy.
Rhythm Pharmaceuticals (NASDAQ: RYTM) Chief Financial Officer Hunter Smith outlined the company's near-term regulatory catalyst, commercial preparation, and pipeline updates during a discussion at Guggenheim's Emerging Outlook Biotech Conference with analyst Seamus Fernandez. Focus on rare neuroendocrine disorders and the MC4R pathway Smith said Rhythm is focused on treating rare neuroendocrine disorders by targeting the melanocortin-4
Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) and BGM Group (NASDAQ: BGM - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of current
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CFO Hunter Smith sold 3,381 shares of the company's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $106.06, for a total transaction of $358,588.86. Following the sale, the chief financial officer directly owned 125,537 shares of the company's
Penserra Capital Management LLC bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 30,436 shares of the company's stock, valued at approximately $3,073,000. A number of other large investors have also recently
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Hunter C. Smith, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 conference on Wednesday, February 11 at 11:00 a.m.
Many investors aren't familiar with Rhythm Pharmaceuticals because of its small size and focus on rare diseases. However, this biotech stock has soared and could rise even more with multiple catalysts on the way.
EFG Asset Management North America Corp. acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the third quarter, according to its most recent filing with the SEC. The fund acquired 20,269 shares of the company's stock, valued at approximately $2,047,000. A number of other large investors have also recently made changes
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- -- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired hypothalamic obesity in first quarter of 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in first quarter of 2026 -- BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary unaudited net product revenues from global sales of IMCIVREE® (setmelanotide) for the fourth quarter and full year of 2025 and upcoming milestones. “2025 was a year of strong execution and reflects significant progress toward our mission of transforming the lives of patients with rare neuroendocrine diseases,” said David Meeker, M.D.
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,700 shares of the company's stock, valued at approximately $677,000. Several other